Tomomi Kogiso

Dr. Tomomi Kogiso

Tokyo Women's Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKTomomi Kogiso
Tomomi Kogiso
KTKatsutoshi Tokushige
Katsutoshi Tokushige
The Fontan operation creates a unique circulation, and is a palliative therapy for patients with single-ventricle congenital heart disease. Increased venous pressure and decreased cardiac output and hepatic venous drainage result in sinusoidal dilatation around the central veins. This causes congestion and hypoxia in the liver, leading to Fontan-associated liver disease (FALD). Non-invasive and invasive markers enable diagnosis and evaluation of the fibrosis status in chronic liver disease; however, these markers have not been validated in FALD. Additionally, regenerative nodules such as focal nodular hyperplasia (FNH) are frequently found. The severity of fibrosis correlates with the duration of the Fontan procedure and the central venous pressure. Cirrhosis is a risk factor for hepatocellular carcinoma (HCC), the annual risk of which is 1.5–5.0%. HCC is frequently difficult to diagnose and treat because of cardiac complications, coagulopathy, and congenital abnormalities. The mortality rate of FALD with liver cirrhosis and/or FALD-HCC was increased to ~ 29.4% (5/17 cases) in a nationwide survey. Although there is no consensus on the surveillance of patients with FALD, serial monitoring of the alpha fetoprotein level and imaging at 6-month intervals is required in patients with cirrhosis.

27 December 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MTMaki Tobari
Maki Tobari
EHEstuko Hashimoto
Estuko Hashimoto
MTMakiko Taniai
Makiko Taniai
YIYuuichi Ikarashi
Yuuichi Ikarashi
KKKazuhisa Kodama
Kazuhisa Kodama
NHNaotake Hashimoto
Naotake Hashimoto

26 March 2020 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
TSTakaomi Sagawa
Takaomi Sagawa
TKTomomi Kogiso
Tomomi Kogiso
HSHisashi Sugiyama
Hisashi Sugiyama
EHEtsuko Hashimoto
Etsuko Hashimoto
MYMasakazu Yamamoto
Masakazu Yamamoto
KTKatsutoshi Tokushige
Katsutoshi Tokushige

9 October 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MTMaki Tobari
Maki Tobari
EHEtsuko Hashimoto
Etsuko Hashimoto
MTMakiko Taniai
Makiko Taniai
KKKazuhisa Kodama
Kazuhisa Kodama
TKTomomi Kogiso
Tomomi Kogiso
ATAraida Tatsuo
Araida Tatsuo

17 June 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTomomi Kogiso
Tomomi Kogiso
TSTakaomi Sagawa
Takaomi Sagawa
MTMakiko Taniai
Makiko Taniai
ESEriko Shimada
Eriko Shimada
KIKei Inai
Kei Inai
KTKatsutoshi Tokushige
Katsutoshi Tokushige
Aims: The incidence of hepatocellular carcinoma (HCC) in patients with Fontan-associated liver disease (i.e., FALD-HCC) has increased over time. However, the risk factors for HCC development remain unclear. Here, we compared the levels of non-invasive markers to the survival rate of FALD-HCC patients. Methods: From 2003 to 2021, 154 patients (66 men, 42.9%) developed liver disease after undergoing Fontan procedures. HCC was diagnosed in 15 (9.7%) (8 men, 53.3%) at a median age of 34 years (range, 21–45 years). We compared FALD-HCC and non-HCC cases; we generated marker level cutoffs using receiver operating characteristic curves. We sought to identify risk factors for HCC and mortality. Results: The incidence of HCC was 4.9% in FALD patients within 20 years after the Fontan procedure. Compared with non-HCC patients, FALD-HCC patients exhibited higher incidences of polysplenia and esophageal varices. At the time of HCC development, the hyaluronic acid (HA) level (p = 0.04) and the fibrosis-4 index (p = 0.02) were significantly higher in FALD-HCC patients than in non-HCC patients; the total bilirubin (T-BIL) level (p = 0.07) and the model for end-stage liver disease score [excluding the international normalized ratio (MELD-XI)] (p = 0.06) tended to be higher in FALD-HCC patients. Within approximately 20 years of the Fontan procedure, 10 patients died (survival rate, 96.9%). Kaplan–Meier curve analysis indicated that patients with T-BIL levels ≥ 2.2 mg/dL, HA levels ≥ 55.5 ng/mL, and MELD-XI scores ≥ 18.7 were at high risk of HCC, a generally poor prognosis, and both polysplenia and esophageal varices. Multivariate Cox regression analyses indicated that the complication of polysplenia [Hazard ratio (HR): 10.915] and a higher MELD-XI score (HR: 1.148, both p < 0.01) were independent risk factors for FALD-HCC. Conclusions: The complication of polysplenia and a MELD-XI score may predict HCC development and mortality in FALD patients.

23 January 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TKTomomi Kogiso
Tomomi Kogiso
TSTakaomi Sagawa
Takaomi Sagawa
KKKazuhisa Kodama
Kazuhisa Kodama
MTMakiko Taniai
Makiko Taniai
EHEtsuko Hashimoto
Etsuko Hashimoto
KTKatsutoshi Tokushige
Katsutoshi Tokushige